Clinical Policy: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Reference Number: HIM.PA.58
Effective Date: 12/14
Last Review Date: 08/17
Line of Business: Health Insurance Marketplace Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following are dipeptidyl peptidase-4 (DPP-4) inhibitors requiring prior authorization: alogliptin (Nesina®), empagliflozin/linagliptin (Glyxambi®), and sitagliptin (Januvia®).

FDA approved indication
DPP-4 inhibitors are indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitation of use:
- DPP-4 inhibitors should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
- DPP-4 inhibitors have not been studied in patients with a history of pancreatitis.

Policy/Criteria
Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria

I. Initial Approval Criteria

A. Type 2 Diabetes Mellitus (must meet all)**:**

1. Diagnosis of type 2 diabetes;
2. Failure of ≥ 3 consecutive months of metformin at doses ≥ 2000 mg/day unless contraindicated or clinically significant adverse effects are experienced;
3. Failure of ≥ 3 consecutive months of a formulary DPP-4 inhibitor (e.g., Onglyza, Tradjenta) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed:
   a. Glyxambi: 5/25 mg/day;
   b. Januvia: 100 mg/day;
   c. Nesina: 25 mg/day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to HIM.PHAR.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Type 2 Diabetes Mellitus (must meet all)**:**
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Documentation of positive response to therapy;
3. If request is for a dose increase, new dose does not exceed:
   a. Glyxambi: 5/25 mg/day;
   b. Januvia: 100 mg/day;
   c. Nesina: 25 mg/day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 12 months (whichever is less); or
2. Refer to HIM.PA.21 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized)

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – HIM.PHAR.21 or evidence of coverage documents
B. Type 1 diabetes mellitus
C. Prediabetes
D. Diabetic ketoacidosis

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
DPP-4: dipeptidyl peptidase-4
FDA: Food and Drug Administration
HbA1c: glycated hemoglobin

Appendix B: HbA1c Goals per ADA Guidelines
According to the American Diabetes Association (ADA), the goal of treatment can be as lenient as HbA1c < 8.5% depending on the patient. Per ADA, HbA1c levels above 8.5% are not recommended as they may expose patients to more frequent high glucose values and acute risks from glycosuria, dehydration, hyperglycemic hyperosmolar syndrome, and poor wound healing.

V. References

1. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017; 40(suppl 1): S1-S135.
2. Glyxambi Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2017. Available at: www.glyxambi.com. Accessed April 27, 2017.
3. Januvia Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; January 2017. Available at: www.januvia.com. Accessed April 27, 2017.

4. Nesina Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; December 2016. Available at: www.nesinafamily.com. Accessed April 27, 2017.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Changed guideline to new format.	08/16	08/16
Added criteria for diagnosis of type 2 diabetes mellitus. Removed age restriction. Removed criteria regarding suboptimal glycemic control as failure of metformin would include suboptimal glycemic control. Added specific dose and duration for metformin trial. Added requirement for failure of a formulary DPP-4. Added max dosing criteria.	04/17	08/17

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.